The pharmaceutical company’s offering was split in eight parts, with maturities ranging from three to 40 years, the people said, asking not to be identified discussing private details. The spread for the longest portion of the deal — a $1 billion note maturing in 2065 — tightened to 1 percentage point above Treasuries, from 1.2 percentage points initially, the people added. ...
Merck Sells $8 Billion in US Bonds Tied to Cidara Deal (2)
December 1, 2025, 9:37 PM UTC
